News

Matt Giegengack, MD, explains how injectable corneal endothelial cell therapy can enhance visual acuity and alleviate glare, offering a versatile alternative to current treatments like DMEK.

In an interview with Ophthalmology Times, Quan Dong Nugyen, MD, MSc, discusses ongoing research into Tinlarebant, an investigational drug being studied as a treatment for Stargardt disease in adolescents.

The investigators conducted a study in which they evaluated the retinal structure in patients with ametropic amblyopia and then correlated it with the final visual acuities achieved after 6 months of follow-up using a multimodal imaging approach.

Abdelrahman Elhusseiny, MD, MSc, sat down with David Hutton of Ophthalmology Times to discuss his presentation on the risk of posterior capsular rupture in fellow eyes of cataract surgery at this year's American Academy of Ophthalmology meeting being held in Chicago, Illinois.

Investigators conducted a retrospective clinical database study that covered 12 years to quantify the risk of PCR in the second eye after PCR developed in the first eye during cataract surgery.

According to data presented in a late-breaking oral presentation at the American Academy of Ophthalmology 2024 Annual Meeting in Chicago.1 efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies.

New research presented at the American Academy of Ophthalmology’s Cornea Subspecialty Day is part of the part of the 8-year Zoster Eye Disease Study.

How cell phone use can affect student retention and attention in the classroom.

A home self-imaging device can provide ophthalmologists with actionable insight between office visits for AMD

Thomas Aaberg Jr, MD sat down to discuss previous presentations by Neurotech at EURETINA and Retina Society as well as upcoming presentations on NT-501 at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.

Non-invasive, painless laser can reduce risk of vision loss

A large study performed in Canada analyzed data and found that patients are at higher risk of multiple possible complications after cataract surgery.

Steven Yeh, MD sat down to discuss his presentation on infectious causes of posterior panuveitis at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.

According to the company, there are no FDA-approved pharmacological therapies for age-related cataracts. Its C-KAD eye drop, improves vision in patients with early-to-moderate cataracts, by penetrating the eye to reduce lens clouding, the main cause for cataracts.

According to data presented this week at the 128th annual meeting of the American Academy of Ophthalmology, being held in Chicago, about three-quarters of medication volume remains in multiuse eye drop bottles tossed in the garbage well before FDA-regulated expiration dates.

The subretinal drusenoid deposits may serve as a biomarker of serious heart disease.

The authors assessed whether a new diagnosis of dry eye increases the risk of developing depression, anxiety, fibromyalgia, and chronic fatigue compared to those without dry eye.

While anxiety and depression may cause vision loss, physicians can offer hope

According to the company, in a confirmatory trial, Epioxa met pre-specified primary efficacy endpoint and exhibited positive tolerability and safety profiles through 12 months, supporting an anticipated NDA submission by the end of 2024.

The Center, which was launched in 2023, will now be named The Barry Family Center for Ophthalmic Artificial Intelligence and Human Health.

A Norwegian study demonstrates that transplant rates continue to drop over time

The DOG recognised Heidelberg Engineering founder Christoph Schoess, Prof Herbert Kaufmann, and Prof Ioannis G. Pallikaris

Centricity Vision announced new ZEPTOLink enhancements, reducing treatment time by up to 60%. These updates, aimed at improving cataract surgery efficiency and control, will be showcased at the 2024 American Academy of Ophthalmology Annual Meeting in Chicago.

David Eichenbaum, MD and Riad Sherif, MD, CEO of Oculis will present the updates with additional info on topline results from the ACUITY Phase 2 trial of OCS-05 for the treatment of acute optic neuritis (AON).

The event will focus on UNITY’s ongoing Phase 2b ASPIRE study, which is evaluating foselutoclax (UBX1325) head-to-head against aflibercept in DME.

Researchers find a strong link between Alzheimer's disease and retinal thinning

The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.

According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks and more broadly in 2025. Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets.